Clinical studies
Clinical studies are necessary in order to be able to offer patients affected by HIV infection access to diagnostics and therapy, as well as information and prophylaxis, at the highest level. They are carried out at several centers worldwide and can provide the necessary information on new drugs and treatment methods. The results of these studies have led to a significant increase in both the chances of survival and the quality of life of HIV patients in recent decades.
The Clinical Department of Rheumatology and Immunology at Hannover Medical School participates in several such studies. New patients can be enrolled in some studies, while patient recruitment has already been completed for others. Our physicians will be at your side to work out an optimal care concept for you and will also provide you with information about the trials you may be eligible for. Patients taking part in clinical trials receive comprehensive care in our outpatient clinic. We see around 680 patients a year.
List of all ongoing studies in our outpatient clinic
| Study name | Study description | Status |
|---|---|---|
| NEAT 22 | cardiovascular risk Dolutegravir (DTG) | ongoing |
| GSK 201637 SWORD | switching to dolutegravir plus rilpivirine from integrase inhibitor-based therapy | ongoing |
| Merck III 1439-018 | Phase III, safety and efficacy of Doravirine (MK-1439) versus Darunavir - extension | ongoing |
| Prophet | pharmacoeconomic study | ongoing |
| Latte-2 | GSK1265744 plus abacavir/lamivudine | ongoing |
| CHIP START | Strategic timing of antiretroviral treatment | ongoing |
| GSK 201585 ATLAS | safety of a two drug regimen of CAB LA + CPV LA compared with maintenance of current ART | ongoing |
| GSK 201584 FLAIR | long-acting intramuscular cabotegravir and rilpivirine | ongoing |
| BMS AI468-038 | Maturation Inhibitor (MI) Study, Phase IIb | ongoing |
| EuroSIDA New Cohort 10 | HIV/HCV co-infected patients | ongoing |
| IDEAL | Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events | terminated |
| Merck II 1439-007 | MK-1439 (NNRTI) Truvada/Sustiva therapy naïve | terminated |
| MARCH STUDY | (Maraviroc Switch collaborative study), University of New South Wales) | terminated |
| PROTEA | Protease inhibitor (DRV/rtv) in mono or triple therapy suppressed HIV infected subjects | terminated |
| GSK ING113086 | Phase III, GSK1349572 (ING) 50 mg once daily to raltegravir 400 mg twice daily | terminated |
| GSK SPRING-1 | Phase II-b study with the new GSK integrase inhibitor | terminated |
| ECHAM | Liver biopsy study | terminated |
| NEAT 001 | Open label randomized two year trial comparing two first-line regimens in HIV infected ART naive subjects: darunavir/r+Tenofovir /emtricitabine vs. darunavir/r+ raltegravir | terminated |
| RKI incidence study | Investigation of risk behavior of HIV pos and neg persons | terminated |
| Jansen Cilag SENSE | Phase IIb etravirine 400 mg qd vs efavirenz 600mg qd in combination with background 2 NRTis comparing neuropsychiatric adverse event profile in naïve pts. | terminated |
| TMC 114 Mono | Open-label DRV/r 800/100 QD vs triple combination DRV/r | terminated |
| VIRO VIR-576 | Phase 1/II Dose escalation study | terminated |
| Study BI 1100.1526 | Nevirapine ER versus Nevirapine IR, randomization 2:1 | terminated |
| Boehringer Ingelheim | Nevirapine extended release 300mg or 400mg QD compared to 200 mg instant release BID in combination with standard background regimen | terminated |
| TMC 278 C 222 | Double blind TMC278 75 mg QD vs Efavirenz 600 mg QD in combination with abacavir and lamivudine | terminated |
| Gilead | Elvitegravir/Cobicistat/FTC/TDF Single tablet | terminated |
| GSK Zoster 015 | I/IIa safety and immunogenicity of GSK herpes zoster vaccine gE/AS01B /Placebo/ 3 doses | terminated |